Trial Profile
A Phase 2 Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) Other Than Predominantly Squamous Cell Histology.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Nov 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 09 Apr 2013 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.